Search research articles
Contact Us
Filters
Showing results (331-340 of 418) with videos related to
Page
of 42
Sort By:
Journal of Psoriasis and Psoriatic Arthritis
|
December 1, 2025
Patient Experiences on the Diagnosis, Management, and Burden of Generalized Pustular Psoriasis: An International Web Survey and Qualitative Interview Study
Mark Lebwohl, Hideki Fujita, Kilian Eyerich, et al.
Dermatology Online Journal
|
October 31, 2025
How Janus kinase selectivity impacts efficacy and safety of abrocitinib for atopic dermatitis: an expert consensus panel
Angela Rosenberg, Danny Zakria, Lauren DeBusk, et al.
RMD Open
|
March 10, 2026
Bimekizumab longer-term safety profile in adult patients with axial spondyloarthritis or psoriatic arthritis: an updated analysis of six phase IIb/III clinical studies
Philip J Mease, Joseph F Merola, Marina Magrey, et al.
Dermatology and Therapy
|
May 14, 2026
Summary of Research: Apremilast Improves Skin Outcomes in Pediatric Plaque Psoriasis of Shorter Disease Duration: 52-Week Results from the SPROUT Phase 3 Trial
Richard G Langley, Lisa Arkin, Loretta Fiorillo, et al.
Journal of Drugs in Dermatology : JDD
|
August 16, 2021
Serious Gastrointestinal-Related Adverse Events Among Psoriasis Patients Treated With Guselkumab in VOYAGE 1 and VOYAGE 2
Peter Foley, Kristian Reich, Andrew Blauvelt, et al.
Journal of the American Academy of Dermatology
|
April 29, 2005
Tacrolimus ointment is more effective than pimecrolimus cream with a similar safety profile in the treatment of atopic dermatitis: results from 3 randomized, comparative studies
Amy S Paller, Mark Lebwohl, Alan B Fleischer, et al.
Lancet (London, England)
|
May 20, 2008
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)
Kim A Papp, Richard G Langley, Mark Lebwohl, et al.
Photochemistry and Photobiology
|
February 6, 2008
p53 gene mutations in SKH-1 mouse tumors differentially induced by UVB and combined subcarcinogenic benzo[a]pyrene and UVA
Yongyin Wang, Xueyan Zhou, Elhav Weinstein, et al.
Journal of Drugs in Dermatology : JDD
|
May 4, 2026
Efficacy and Safety of Cosibelimab for Advanced Cutaneous Squamous Cell Carcinoma: An Expert Consensus Panel
Brooke Bartley, Angela Rosenberg, Lauren DeBusk, et al.
The New England Journal of Medicine
|
April 23, 2021
Bimekizumab versus Secukinumab in Plaque Psoriasis
Kristian Reich, Richard B Warren, Mark Lebwohl, et al.
Page
of 42
Search research articles
Search
Showing results (331-340 of 418) with videos related to
Sort By:
Page
of 42
Journal of Psoriasis and Psoriatic Arthritis
|
December 1, 2025
Patient Experiences on the Diagnosis, Management, and Burden of Generalized Pustular Psoriasis: An International Web Survey and Qualitative Interview Study
Mark Lebwohl, Hideki Fujita, Kilian Eyerich, et al.
Dermatology Online Journal
|
October 31, 2025
How Janus kinase selectivity impacts efficacy and safety of abrocitinib for atopic dermatitis: an expert consensus panel
Angela Rosenberg, Danny Zakria, Lauren DeBusk, et al.
RMD Open
|
March 10, 2026
Bimekizumab longer-term safety profile in adult patients with axial spondyloarthritis or psoriatic arthritis: an updated analysis of six phase IIb/III clinical studies
Philip J Mease, Joseph F Merola, Marina Magrey, et al.
Dermatology and Therapy
|
May 14, 2026
Summary of Research: Apremilast Improves Skin Outcomes in Pediatric Plaque Psoriasis of Shorter Disease Duration: 52-Week Results from the SPROUT Phase 3 Trial
Richard G Langley, Lisa Arkin, Loretta Fiorillo, et al.
Journal of Drugs in Dermatology : JDD
|
August 16, 2021
Serious Gastrointestinal-Related Adverse Events Among Psoriasis Patients Treated With Guselkumab in VOYAGE 1 and VOYAGE 2
Peter Foley, Kristian Reich, Andrew Blauvelt, et al.
Journal of the American Academy of Dermatology
|
April 29, 2005
Tacrolimus ointment is more effective than pimecrolimus cream with a similar safety profile in the treatment of atopic dermatitis: results from 3 randomized, comparative studies
Amy S Paller, Mark Lebwohl, Alan B Fleischer, et al.
Lancet (London, England)
|
May 20, 2008
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)
Kim A Papp, Richard G Langley, Mark Lebwohl, et al.
Photochemistry and Photobiology
|
February 6, 2008
p53 gene mutations in SKH-1 mouse tumors differentially induced by UVB and combined subcarcinogenic benzo[a]pyrene and UVA
Yongyin Wang, Xueyan Zhou, Elhav Weinstein, et al.
Journal of Drugs in Dermatology : JDD
|
May 4, 2026
Efficacy and Safety of Cosibelimab for Advanced Cutaneous Squamous Cell Carcinoma: An Expert Consensus Panel
Brooke Bartley, Angela Rosenberg, Lauren DeBusk, et al.
The New England Journal of Medicine
|
April 23, 2021
Bimekizumab versus Secukinumab in Plaque Psoriasis
Kristian Reich, Richard B Warren, Mark Lebwohl, et al.
Page
of 42